Tarik Esen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Tarik Esen has a total of 123 co-authors. Here are the top co-authors by number of shared publications:
- Mert Kılıç
American Hospital, Urology Department
11 shared publications - Ömer Acar
Department of Urology University of Illinois Chicago Illinois USA
11 shared publications - Metin Vural
Department of Radiology, VKF American Hospital, Istanbul, Turkey
9 shared publications - Ersin Köseoğlu
Department of Urology, School of Medicine Koc University Istanbul Turkey
8 shared publications - Murat Can Kiremit
Department of Urology, School of Medicine, Koc University, Istanbul, Turkey
8 shared publications - Yakup Kordan
KOÇ ÜNİVERSİTESİ, TIP FAKÜLTESİ, CERRAHİ TIP BİLİMLERİ BÖLÜMÜ, ÜROLOJİ ANABİLİM DALI
8 shared publications
Latest Publications
- 1 December 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 8
Optimizing prostate biopsy: the role of targeted, regional, and systematic approaches
- 1 December 2025
- Published by Springer Nature in World Journal of Urology
- Vol. 44 (1) , 8
Optimizing prostate biopsy: the role of targeted, regional, and systematic approaches
- Open Access
- 20 May 2025
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 32 (1) , 8-15
The role of T1 hyperintensity in differentiating granulomatous prostatitis from prostate cancer: a retrospective analysis of 31 lesions
To investigate the multiparametric magnetic resonance imaging (mpMRI) characteristics of granulomatous prostatitis (GP) and share our experience with 31 pathologically confirmed GP lesions in 19 patients. This two-center retrospective study reviewed the pathological and imaging data of 856 patients who underwent prostate biopsy between January 2012 and April 2024. Of these, 19 patients with available prebiopsy mpMRI and a pathologically confirmed diagnosis of GP were included. Additionally, 280 biopsy-naïve patients diagnosed with clinically significant prostate cancer (csPCa) were included as a control group for comparative analysis. Prebiopsy mpMR images of patients with GP were assessed by consensus between two of three radiologists (M.V., B.C., S.D.), evaluating lesion location, size, shape, multifocality, extraprostatic extension (EPE), signal characteristics on T1-, T2-, and diffusion-weighted imaging (DWI), the mean apparent diffusion coefficient (ADCmean) value, enhancement patterns, and prostate imaging reporting and data system (PI-RADS) scores. Statistical analyses were conducted using SPSS version 30.0. In 19 patients, 31 pathologically confirmed GP lesions were identified on prebiopsy mpMRI. Twenty-six lesions were located in the peripheral zone and five in the transitional zone. Multifocal involvement was observed in nine patients (47.3%). Thirty of 31 lesions were hypointense on T2-WI, and seven showed capsular bulging and/or irregularity, suggesting EPE. DWI revealed markedly impeded diffusion in all lesions. The median ADCmean value was 825 × 10-3 mm2/s (IQR: 230 × 10-3 mm2/s). On dynamic contrast-enhanced sequences, 25 lesions showed early enhancement, five showed prolonged enhancement, and one showed prolonged ring enhancement. Based on mpMRI findings, 17 lesions were assigned a PI-RADS score of 4, and 13 lesions were assigned a PI-RADS score of 5. Notably, 22 lesions (71%) in 14 patients with GP (73.7%) exhibited hyperintensity on T1-WI despite no prior prostate biopsy history. Statistical analysis comparing the GP and csPCa groups revealed that hyperintensity on T1-WI was significantly more frequent in GP, both on a per-patient basis (73.7% vs. 3.2%) and a per-lesion basis (71.0% vs. 3.1%) (P < 0.0001 for both). GP shares overlapping imaging features with prostate cancer on mpMRI. However, hyperintensity on T1-WI may serve as a distinguishing feature, potentially reducing unnecessary prostate interventions. Radiologists should consider GP in PI-RADS ≥4 lesions exhibiting T1-WI hyperintensity. Furthermore, given the high incidence of GP following intravesical Bacillus Calmette-Guérin (BCG) therapy, a thorough history of BCG treatment should be obtained. GP is recognized for its tendency to mimic PCa on mpMRI, a finding corroborated by this study. However, T1-WI hyperintensity emerged as a promising distinguishing feature for GP. Incorporating this marker into mpMRI interpretation criteria may help reduce unnecessary prostate interventions and improve patient outcomes.
- 20 May 2025
- Published by Galenos Yayinevi in Diagnostic and Interventional Radiology
- Vol. 32 (1) , 8-15
Open AccessThe role of T1 hyperintensity in differentiating granulomatous prostatitis from prostate cancer: a retrospective analysis of 31 lesions
To investigate the multiparametric magnetic resonance imaging (mpMRI) characteristics of granulomatous prostatitis (GP) and share our experience with 31 pathologically confirmed GP lesions in 19 patients. This two-center retrospective study reviewed the pathological and imaging data of 856 patients who underwent prostate biopsy between January 2012 and April 2024. Of these, 19 patients with available prebiopsy mpMRI and a pathologically confirmed diagnosis of GP were included. Additionally, 280 biopsy-naïve patients diagnosed with clinically significant prostate cancer (csPCa) were included as a control group for comparative analysis. Prebiopsy mpMR images of patients with GP were assessed by consensus between two of three radiologists (M.V., B.C., S.D.), evaluating lesion location, size, shape, multifocality, extraprostatic extension (EPE), signal characteristics on T1-, T2-, and diffusion-weighted imaging (DWI), the mean apparent diffusion coefficient (ADCmean) value, enhancement patterns, and prostate imaging reporting and data system (PI-RADS) scores. Statistical analyses were conducted using SPSS version 30.0. In 19 patients, 31 pathologically confirmed GP lesions were identified on prebiopsy mpMRI. Twenty-six lesions were located in the peripheral zone and five in the transitional zone. Multifocal involvement was observed in nine patients (47.3%). Thirty of 31 lesions were hypointense on T2-WI, and seven showed capsular bulging and/or irregularity, suggesting EPE. DWI revealed markedly impeded diffusion in all lesions. The median ADCmean value was 825 × 10-3 mm2/s (IQR: 230 × 10-3 mm2/s). On dynamic contrast-enhanced sequences, 25 lesions showed early enhancement, five showed prolonged enhancement, and one showed prolonged ring enhancement. Based on mpMRI findings, 17 lesions were assigned a PI-RADS score of 4, and 13 lesions were assigned a PI-RADS score of 5. Notably, 22 lesions (71%) in 14 patients with GP (73.7%) exhibited hyperintensity on T1-WI despite no prior prostate biopsy history. Statistical analysis comparing the GP and csPCa groups revealed that hyperintensity on T1-WI was significantly more frequent in GP, both on a per-patient basis (73.7% vs. 3.2%) and a per-lesion basis (71.0% vs. 3.1%) (P < 0.0001 for both). GP shares overlapping imaging features with prostate cancer on mpMRI. However, hyperintensity on T1-WI may serve as a distinguishing feature, potentially reducing unnecessary prostate interventions. Radiologists should consider GP in PI-RADS ≥4 lesions exhibiting T1-WI hyperintensity. Furthermore, given the high incidence of GP following intravesical Bacillus Calmette-Guérin (BCG) therapy, a thorough history of BCG treatment should be obtained. GP is recognized for its tendency to mimic PCa on mpMRI, a finding corroborated by this study. However, T1-WI hyperintensity emerged as a promising distinguishing feature for GP. Incorporating this marker into mpMRI interpretation criteria may help reduce unnecessary prostate interventions and improve patient outcomes.
- Open Access
- 26 April 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (17) , e37975
The effect of ultrasound-guided rectus sheath block on postoperative analgesia in robot assisted prostatectomy: A randomized controlled trial
Background: Postoperative pain continues to represent an important problem even after minimally invasive robotic-assisted laparoscopic radical prostatectomy, which results in discomfort in the postoperative period and sometimes prolongs hospital stays. Regional anesthesia and analgesia techniques are used in addition to systemic analgesics with the multimodal approach in postoperative pain management. Ultrasound-guided fascial plane blocks are becoming increasingly important, especially in minimally invasive surgeries. Another important cause of discomfort is urinary catheter pain. The present randomized controlled study investigated the effect of rectus sheath block on postoperative pain and catheter-related bladder discomfort in robotic prostatectomy operations. Methods: This randomized controlled trial was conducted from March to August 2022. Written informed consent was obtained from all participants. Approval for the study was granted by the Clinical Research Ethics Committee. All individuals provided written informed consent, and adults with American Society of Anesthesiologists Physical Condition classification I to III planned for robotic prostatectomy operations under general anesthesia were enrolled. Following computer-assisted randomization, patients were divided into 2 groups, and general anesthesia was induced in all cases. Rectus sheath block was performed under general anesthesia and at the end of the surgery. No fascial plane block was applied to the patients in the non-rectus sheath block (RSB) group. Postoperative pain and urinary catheter pain were assessed using a numerical rating scale. Fentanyl was planned as rescue analgesia in the recovery room. In case of numerical rating scale scores of 4 or more, patients were given 50 µg fentanyl IV, repeated if necessary. The total fentanyl dose administered was recorded in the recovery room. IV morphine patient-controlled analgesia was planned for all patients. All patients’ pain (postoperative pain at surgical site and urethral catheter discomfort) scores and total morphine consumption in the recovery unit and during follow-ups on the ward (3, 6, 12, and 24 hours) in the postoperative period were recorded. Results: Sixty-one patients were evaluated. Total tramadol consumption during follow-up on the ward was significantly higher in the non-RSB group. Fentanyl consumption in the postanesthesia care unit was significantly higher in the non-RSB group. Total morphine consumption was significantly lower in the RSB group at 0 to 12 hours and 12 to 24 hours. Total opioid consumption was 8.81 mg in the RSB group and 19.87 mg in the non-RSB group. A statistically significant decrease in urethral catheter pain was noted in the RSB group at all time points. Conclusion: RSB exhibits effective analgesia by significantly reducing postoperative opioid consumption in robotic prostatectomy operations.
- 26 April 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (17) , e37975
Open AccessThe effect of ultrasound-guided rectus sheath block on postoperative analgesia in robot assisted prostatectomy: A randomized controlled trial
Background: Postoperative pain continues to represent an important problem even after minimally invasive robotic-assisted laparoscopic radical prostatectomy, which results in discomfort in the postoperative period and sometimes prolongs hospital stays. Regional anesthesia and analgesia techniques are used in addition to systemic analgesics with the multimodal approach in postoperative pain management. Ultrasound-guided fascial plane blocks are becoming increasingly important, especially in minimally invasive surgeries. Another important cause of discomfort is urinary catheter pain. The present randomized controlled study investigated the effect of rectus sheath block on postoperative pain and catheter-related bladder discomfort in robotic prostatectomy operations. Methods: This randomized controlled trial was conducted from March to August 2022. Written informed consent was obtained from all participants. Approval for the study was granted by the Clinical Research Ethics Committee. All individuals provided written informed consent, and adults with American Society of Anesthesiologists Physical Condition classification I to III planned for robotic prostatectomy operations under general anesthesia were enrolled. Following computer-assisted randomization, patients were divided into 2 groups, and general anesthesia was induced in all cases. Rectus sheath block was performed under general anesthesia and at the end of the surgery. No fascial plane block was applied to the patients in the non-rectus sheath block (RSB) group. Postoperative pain and urinary catheter pain were assessed using a numerical rating scale. Fentanyl was planned as rescue analgesia in the recovery room. In case of numerical rating scale scores of 4 or more, patients were given 50 µg fentanyl IV, repeated if necessary. The total fentanyl dose administered was recorded in the recovery room. IV morphine patient-controlled analgesia was planned for all patients. All patients’ pain (postoperative pain at surgical site and urethral catheter discomfort) scores and total morphine consumption in the recovery unit and during follow-ups on the ward (3, 6, 12, and 24 hours) in the postoperative period were recorded. Results: Sixty-one patients were evaluated. Total tramadol consumption during follow-up on the ward was significantly higher in the non-RSB group. Fentanyl consumption in the postanesthesia care unit was significantly higher in the non-RSB group. Total morphine consumption was significantly lower in the RSB group at 0 to 12 hours and 12 to 24 hours. Total opioid consumption was 8.81 mg in the RSB group and 19.87 mg in the non-RSB group. A statistically significant decrease in urethral catheter pain was noted in the RSB group at all time points. Conclusion: RSB exhibits effective analgesia by significantly reducing postoperative opioid consumption in robotic prostatectomy operations.
- Open Access
- 1 January 2024
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 50 (5) , 275-280
Revisiting Skull Metastases of Prostate Cancer at Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography Era: PSMA Uptake Characteristics and Oncological Outcomes
Objective: We aimed to evaluate prostate-specific membrane antigen (PSMA) uptake characteristics and the oncological outcomes in patients with skull metastases. Methods: The records of 345 serial PSMA positron emission tomography (PET)/computed tomography (CT) scans of 96 patients with metastatic prostate cancer (PCa) were evaluated retrospectively. Skull bone metastasis was detected in 18 patients (18/96, 18.7%), with a mean age of 72.4 Å} 9.1 years, and in 40 PSMA PET/CT scans (40/345, 11.6%). Involved skull bones, PSMA uptake characteristics, and CT counterparts of metastatic lesions were centrally reviewed. Prostate specific antigen (PSA) levels at the time of skull metastasis detection and PSMA-detected other metastatic lesions were recorded. Results: All patients with a skull metastasis showed multiple other metastatic bon lesions, and 6 (33.3%) had visceral metastasis. Seven (38.9%) patients had solitary skull lesions, whereas 11 (61.1%) had multiple skull metastases. Twenty-two out of 37 (59.5%) metastatic lesions had no CT counterpart. The median SUVmax was significantly higher in metastatic lesions with a CT counterpart (median 9.09 vs. 4.63, P = .018). At a median follow-up of 23.4 mo (interquartile range [IQR] 8.7-34.1) after detection of skull metastasis, 5 out of 11 (45.5%) hormone-sensitive and all castration-resistant patients died of PCa. The median survival of patients with castration-resistant disease was 9.92 months. Conclusion: The majority of PSMA-detected skull metastases did not show a CT counterpart, which may explain why skull metastases were rarely detected before the PSMA PET-era. In high-volume metastatic prostatic cancer cases, 68Ga-PSMA PET/CT imaging field including the vertex, may enhance the accuracy in detecting tumor extent and metabolic tumor volume. Cite this article as: Esen B, Falay O, Tarim K, et al. Revisiting skull metastases of prostate cancer at prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography era: PSMA uptake characteristics and oncological outcomes. Urol Res Pract. 2024;50(5):275-280.
- 1 January 2024
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 50 (5) , 275-280
Open AccessRevisiting Skull Metastases of Prostate Cancer at Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography Era: PSMA Uptake Characteristics and Oncological Outcomes
Objective: We aimed to evaluate prostate-specific membrane antigen (PSMA) uptake characteristics and the oncological outcomes in patients with skull metastases. Methods: The records of 345 serial PSMA positron emission tomography (PET)/computed tomography (CT) scans of 96 patients with metastatic prostate cancer (PCa) were evaluated retrospectively. Skull bone metastasis was detected in 18 patients (18/96, 18.7%), with a mean age of 72.4 Å} 9.1 years, and in 40 PSMA PET/CT scans (40/345, 11.6%). Involved skull bones, PSMA uptake characteristics, and CT counterparts of metastatic lesions were centrally reviewed. Prostate specific antigen (PSA) levels at the time of skull metastasis detection and PSMA-detected other metastatic lesions were recorded. Results: All patients with a skull metastasis showed multiple other metastatic bon lesions, and 6 (33.3%) had visceral metastasis. Seven (38.9%) patients had solitary skull lesions, whereas 11 (61.1%) had multiple skull metastases. Twenty-two out of 37 (59.5%) metastatic lesions had no CT counterpart. The median SUVmax was significantly higher in metastatic lesions with a CT counterpart (median 9.09 vs. 4.63, P = .018). At a median follow-up of 23.4 mo (interquartile range [IQR] 8.7-34.1) after detection of skull metastasis, 5 out of 11 (45.5%) hormone-sensitive and all castration-resistant patients died of PCa. The median survival of patients with castration-resistant disease was 9.92 months. Conclusion: The majority of PSMA-detected skull metastases did not show a CT counterpart, which may explain why skull metastases were rarely detected before the PSMA PET-era. In high-volume metastatic prostatic cancer cases, 68Ga-PSMA PET/CT imaging field including the vertex, may enhance the accuracy in detecting tumor extent and metabolic tumor volume. Cite this article as: Esen B, Falay O, Tarim K, et al. Revisiting skull metastases of prostate cancer at prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography era: PSMA uptake characteristics and oncological outcomes. Urol Res Pract. 2024;50(5):275-280.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Quantitative Proteomics Identifies Secreted Diagnostic Biomarkers as well as Tumor-Dependent Prognostic Targets for Clear Cell Renal Cell Carcinoma
Supplementary Data from Quantitative Proteomics Identifies Secreted Diagnostic Biomarkers as well as Tumor-Dependent Prognostic Targets for Clear Cell Renal Cell Carcinoma
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Quantitative Proteomics Identifies Secreted Diagnostic Biomarkers as well as Tumor-Dependent Prognostic Targets for Clear Cell Renal Cell Carcinoma
Supplementary Data from Quantitative Proteomics Identifies Secreted Diagnostic Biomarkers as well as Tumor-Dependent Prognostic Targets for Clear Cell Renal Cell Carcinoma
- 3 January 2023
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (2) , 449-454
The role of the size and number of index lesion in the diagnosis of clinically significant prostate cancer in patients with PI-RADS 4 lesions who underwent in-bore MRI-guided prostate biopsy
Purpose To evaluate the contribution of the size and number of the sampled lesions to the diagnosis of clinically significant prostate cancer (CSPC) in patients who had PI-RADS 4 lesions. Methods In this retrospective study, a total of 159 patients who had PI-RADS 4 lesions and underwent In-bore MRI-Guided prostate biopsy were included. Patients with a lesion classified as Grade Group 2 and above were considered to have CSPC. Univariate and multivariate regression analyses were used to evaluate the factors affecting the diagnosis of prostate cancer (PCa) and CSPC. Results A great majority (86.8%) of the patients were biopsy-naïve. About three-fourths (71.7%) had PCa, and half (54.1%) had CSPC. When the patients were divided into three groups according to the index lesion size (< 5 mm, 5–10 mm, and > 10 mm), the prevalence of PCa was 64.3, 67.5, and 82.4% and the prevalence of CSPC was 42.9, 51.2, and 64.7%, respectively. In multivariate analysis, age, index lesion size, prostate volume (< 50 ml) and being biopsy-naïve were found significant for PCa, while age and prostate volume (< 50 ml) were significant for CSPC. Conclusion The number of lesions was found to be insignificant in predicting PCa and CSPC. While the size of PI-RADS 4 lesions was significant in predicting PCa, it had no significance in detecting CSPC.
- 3 January 2023
- Published by Springer Nature in World Journal of Urology
- Vol. 41 (2) , 449-454
The role of the size and number of index lesion in the diagnosis of clinically significant prostate cancer in patients with PI-RADS 4 lesions who underwent in-bore MRI-guided prostate biopsy
Purpose To evaluate the contribution of the size and number of the sampled lesions to the diagnosis of clinically significant prostate cancer (CSPC) in patients who had PI-RADS 4 lesions. Methods In this retrospective study, a total of 159 patients who had PI-RADS 4 lesions and underwent In-bore MRI-Guided prostate biopsy were included. Patients with a lesion classified as Grade Group 2 and above were considered to have CSPC. Univariate and multivariate regression analyses were used to evaluate the factors affecting the diagnosis of prostate cancer (PCa) and CSPC. Results A great majority (86.8%) of the patients were biopsy-naïve. About three-fourths (71.7%) had PCa, and half (54.1%) had CSPC. When the patients were divided into three groups according to the index lesion size (< 5 mm, 5–10 mm, and > 10 mm), the prevalence of PCa was 64.3, 67.5, and 82.4% and the prevalence of CSPC was 42.9, 51.2, and 64.7%, respectively. In multivariate analysis, age, index lesion size, prostate volume (< 50 ml) and being biopsy-naïve were found significant for PCa, while age and prostate volume (< 50 ml) were significant for CSPC. Conclusion The number of lesions was found to be insignificant in predicting PCa and CSPC. While the size of PI-RADS 4 lesions was significant in predicting PCa, it had no significance in detecting CSPC.
- 21 December 2022
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 17 (3) , 785-795
Experiences of perioperative nurses with robotic-assisted surgery: a systematic review of qualitative studies
To determine the experiences of perioperative nurses with robotic-assisted surgery is needed to improve the robotic-assisted surgery practices. This study systematically reviewed and analysed the qualitative studies concerning perioperative nurses’ experiences of robotic-assisted surgery. This systematic literature review included studies up to December 2020. The study data were analysed using inductive content analysis. This systematic review included six articles. There were a total of 71 nurses who participated in the included articles (min = 6, max = 17). Their mean age was 35.7, and their experience in robotic-assisted surgery ranged from 8 months to 10 years. Content analysis generated six categories: adaptation to robotic-assisted surgery technology, the importance of teamwork in robotic-assisted surgery, changing tasks and responsibilities in robotic-assisted surgery, training requirements for robotic-assisted surgery, the effects of robotic-assisted surgery on patients and patient safety, and difficulties with robotic-assisted surgery. A variety of themes and sub-themes emerged in these categories. The review highlights the importance of developing new ways of thinking about the assessment and management of disruptions, developing different teamwork patterns and communication skills, and overcoming the challenges involved in technologically advanced surgeries. Nurses’ roles in robotic technology should be redefined in healthcare. Nurses should learn how to adapt to advancing technology and how to supplement and enhance their skills.
- 21 December 2022
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 17 (3) , 785-795
Experiences of perioperative nurses with robotic-assisted surgery: a systematic review of qualitative studies
To determine the experiences of perioperative nurses with robotic-assisted surgery is needed to improve the robotic-assisted surgery practices. This study systematically reviewed and analysed the qualitative studies concerning perioperative nurses’ experiences of robotic-assisted surgery. This systematic literature review included studies up to December 2020. The study data were analysed using inductive content analysis. This systematic review included six articles. There were a total of 71 nurses who participated in the included articles (min = 6, max = 17). Their mean age was 35.7, and their experience in robotic-assisted surgery ranged from 8 months to 10 years. Content analysis generated six categories: adaptation to robotic-assisted surgery technology, the importance of teamwork in robotic-assisted surgery, changing tasks and responsibilities in robotic-assisted surgery, training requirements for robotic-assisted surgery, the effects of robotic-assisted surgery on patients and patient safety, and difficulties with robotic-assisted surgery. A variety of themes and sub-themes emerged in these categories. The review highlights the importance of developing new ways of thinking about the assessment and management of disruptions, developing different teamwork patterns and communication skills, and overcoming the challenges involved in technologically advanced surgeries. Nurses’ roles in robotic technology should be redefined in healthcare. Nurses should learn how to adapt to advancing technology and how to supplement and enhance their skills.
- Open Access
- 26 September 2022
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 4 (3) , 172-177
Gardnerella vaginalis: Is it an Underestimated Cause of Urinary Symptoms in Males?
Objective: This study aimed t o investigate the detection rate of Gardnerella vaginalis by multiplex PCR test in the genitourinary samples of male patients with suspected urethritis and related symptoms. Materials and Methods: A total of 144 male patients who presented to our department between February 2021 and October 2021, either with urinary symptoms or concerns following unprotected sex, were included in the study. A total of 128 (88.9%) first-void urine samples, 15 (10.4%) urethral swabs, and one (0.7%) semen sample were obtained. NeoPlex STI-14 Detection Multiplex PCR Kit (GeneMatrix Inc. Seongnam, South Korea) was used to investigate any of the following pathogens: Candida albicans, Chlamydia trachomatis, G. vaginalis, Mycoplasma genitalium, Mycoplasma hominis, Neisseria gonorrhoeae, Trichomonas vaginalis, Ureaplasma parvum, Ureaplasma urealyticum, herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), Treponema pallidum, Streptococcus agalactiae, and Haemophilus ducreyi. The patients with positive results for G. vaginalis were retrospectively analyzed. Results: The patients’ median age was 37 (range: 21 to 71 years old). G. vaginalis was the most frequently detected microorganism (n=23; 15.9%). Other microorganisms found in order of frequency were U. urealyticum (n=19; 13.2%), U. parvum (n=15; 10.4%), C. trachomatis (n=11; 7.6%), M. genitalium (n=8; 5.6%), HSV-2 (n= 7; 4.9%), N. gonorrhoeae (n=6; 4.2), HSV-1 (n=2; 1.4%), M. hominis (n=1, 0.7%), and C. albicans (n=1, 0.7%). Fifteen patients (65%) were positive for one or two microbial agents together with G. vaginalis, while in eight patients (35%), G. vaginalis was the only isolated agent. Six of these eight patients and 14 of the remaining 15 were symptomatic. Conclusion: With the introduction of multiplex PCR tests, including those for G. vaginalis, we can expect a higher detection rate of these species of bacteria in male genitourinary samples, which could be the cause of unexplained urinary/urethral symptoms. Keywords: Gardnerella vaginalis, male, polymerase chain reaction, urethritis
- 26 September 2022
- Published by Doc Design and Informatics Co. Ltd. in Infectious Diseases and Clinical Microbiology
- Vol. 4 (3) , 172-177
Open AccessGardnerella vaginalis: Is it an Underestimated Cause of Urinary Symptoms in Males?
Objective: This study aimed t o investigate the detection rate of Gardnerella vaginalis by multiplex PCR test in the genitourinary samples of male patients with suspected urethritis and related symptoms. Materials and Methods: A total of 144 male patients who presented to our department between February 2021 and October 2021, either with urinary symptoms or concerns following unprotected sex, were included in the study. A total of 128 (88.9%) first-void urine samples, 15 (10.4%) urethral swabs, and one (0.7%) semen sample were obtained. NeoPlex STI-14 Detection Multiplex PCR Kit (GeneMatrix Inc. Seongnam, South Korea) was used to investigate any of the following pathogens: Candida albicans, Chlamydia trachomatis, G. vaginalis, Mycoplasma genitalium, Mycoplasma hominis, Neisseria gonorrhoeae, Trichomonas vaginalis, Ureaplasma parvum, Ureaplasma urealyticum, herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), Treponema pallidum, Streptococcus agalactiae, and Haemophilus ducreyi. The patients with positive results for G. vaginalis were retrospectively analyzed. Results: The patients’ median age was 37 (range: 21 to 71 years old). G. vaginalis was the most frequently detected microorganism (n=23; 15.9%). Other microorganisms found in order of frequency were U. urealyticum (n=19; 13.2%), U. parvum (n=15; 10.4%), C. trachomatis (n=11; 7.6%), M. genitalium (n=8; 5.6%), HSV-2 (n= 7; 4.9%), N. gonorrhoeae (n=6; 4.2), HSV-1 (n=2; 1.4%), M. hominis (n=1, 0.7%), and C. albicans (n=1, 0.7%). Fifteen patients (65%) were positive for one or two microbial agents together with G. vaginalis, while in eight patients (35%), G. vaginalis was the only isolated agent. Six of these eight patients and 14 of the remaining 15 were symptomatic. Conclusion: With the introduction of multiplex PCR tests, including those for G. vaginalis, we can expect a higher detection rate of these species of bacteria in male genitourinary samples, which could be the cause of unexplained urinary/urethral symptoms. Keywords: Gardnerella vaginalis, male, polymerase chain reaction, urethritis